TreeFrog Therapeutics

Confidence in a potential curative treatment for Type 1 diabetes is growing after Vertex showed three people given its cell therapy, VX-880, lived without insulin injections for a year. New data fro

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Bristol Looks Into Tolerizing Vaccines,

Lightstone Ventures has closed its third fund – its largest to date – with $375m to fund early stage biopharmaceutical and medical technology companies after several successful exits via initial publi